Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 11/20 | 0.71 |
| ▸ | KDR | P35968 | 3/20 | 0.71 |
| ▸ | BRAF | P15056 | 4/20 | 0.59 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 3/20 | 0.45 |
| ▸ | FLT3 | P36888 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3546156 | 0.91 | RAF1 (0.64) | RAF1KDRBRAFRIPK2MAPK14 | |
| SCHEMBL14422914 | 0.87 | RAF1 (0.82) | RAF1KDRBRAFRIPK2EPHX2 | |
| SCHEMBL15574401 | 0.85 | RAF1 (0.77) | RAF1KDRRIPK2EPHX2MAPK14 | |
| SCHEMBL3542762 | 0.85 | RAF1 (0.58) | RAF1KDRBRAFRIPK2EPHX2 | |
| SCHEMBL13234850 | 0.83 | RAF1 (1.00) | RAF1KDRBRAFRIPK2EPHX2 | |
| SCHEMBL14422915 | 0.82 | RAF1 (0.68) | RAF1KDRBRAFMAPK14MAPK13 | |
| SCHEMBL3538127 | 0.81 | RAF1 (0.67) | RAF1KDRBRAFRIPK2EPHX2 | |
| SCHEMBL3551325 | 0.80 | BRAF (0.68) | RAF1KDRBRAFEPHX2MAPK14 | |
| SCHEMBL3545659 | 0.80 | RAF1 (0.59) | RAF1KDRBRAFEPHX2MAPK14 | |
| SCHEMBL3550254 | 0.80 | BRAF (0.59) | RAF1KDRBRAFEPHX2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652041-B2 | 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | claimed |
| US-7652041-B2 | 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652041-B2 | 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20060160803-A1 | Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160803-A1 | Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity | MAP3K21, HIPK4, MAP3K20 | RAF1 693/4885KDR 729/4885BRAF 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.